基本信息
浏览量:1
职业迁徙
个人简介
Dr. Schwendeman’s long-term research goal is to design highly potent and safe synthetic high-density lipoprotein (HDL) nanomedicines for treatment of atherosclerosis. Dr. Schwendeman spent 12 years in pharmaceutical industry at Cerenis Therapeutics, Pfizer, and Esperion Therapeutics. She was involved in discovery and translation of several HDL therapies to Phase II clinical trials. Her efforts led to development of a kilo-scale recombinant process for Apolipoprotein A-I process and highly homogeneous HDL particles (CER-001) for the largest-to-date Phase II sHDL clinical trial (>500 patients). She successfully submitted FDA INDs for six different products including nanoparticles, liposome, proteins, peptides and small molecule.
Her current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency, and designing of ApoA-I mimic peptides. Her laboratory has several ongoing translational collaborative projects focused on assessing sHDL utility for treatment of Alzheimer's disease, sepsis, acute lung injury and lupus. Dr. Schwendeman also explores the utility of these “nature-made” nanoparticles for targeted delivery of chemotherapeutics, siRNA, micro RNA and peptide antigens. Finally, her laboratory is active in developing science-based regulations for testing of complex parenteral products such as nanoparticles, recombinant proteins and microspheres. Research is currently supported by grants from the American Heart Association, Food and Drug Administration and U-M Michigan Translational Research and Commercialization for Life Sciences Program (U-M MTRAC).
Her current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency, and designing of ApoA-I mimic peptides. Her laboratory has several ongoing translational collaborative projects focused on assessing sHDL utility for treatment of Alzheimer's disease, sepsis, acute lung injury and lupus. Dr. Schwendeman also explores the utility of these “nature-made” nanoparticles for targeted delivery of chemotherapeutics, siRNA, micro RNA and peptide antigens. Finally, her laboratory is active in developing science-based regulations for testing of complex parenteral products such as nanoparticles, recombinant proteins and microspheres. Research is currently supported by grants from the American Heart Association, Food and Drug Administration and U-M Michigan Translational Research and Commercialization for Life Sciences Program (U-M MTRAC).
研究兴趣
论文共 29 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Pharmaceutical Researchno. 2 (2024): 293-303
Ahmed O. Elzoghby, Omar Samir, Ahmed Soliman,Sergey Solomevich,Minzhi Yu,Anna Schwendeman,Mahmoud L. Nasr
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn